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Background: Significant advancements in percutaneous coronary intervention (PCI) and adjuvant pharmacotherapy have taken place over the past 
decade. Limited data exist on long-term outcomes of patients following PCI for both acute coronary syndrome (ACS) and non-ACS patients in this era.
Methods: We assessed demographic, angiographic, and 5-year outcome data of 5,708 stented patients enrolled the NHLBI Dynamic Registry in 
1999 (cohort 2), 2004 (cohort 4) and 2006 (cohort 5).
Results: Patients in later cohorts had more complex coronary artery disease, a higher prevalence and severity of comorbid conditions, as well as 
significantly higher use of dual antiplatelet agents, ACE inhibitors, beta blockers, and statin therapy at discharge. Patients in the later cohorts were 
also significantly more likely to have diabetes, renal insufficiency, hypertension, hyperlipidemia, and more relied on public assistance for healthcare. 
Over time, significantly more type-C coronary lesions were attempted, patients were more likely to have undergone multiple prior revascularization 
procedures, and were more likely to present with significant left main stenosis and multi-vessel disease. By five years, there was no significant 
difference in death (adjusted HR 0.97, p=0.74 for cohort 2 vs. cohort 4 and adjusted HR 0.89, p=0.25 for cohort 2 vs. cohort 5), or myocardial 
infarction (adjusted HR 0.89, p=0.28 for cohort 2 vs cohort 4 and adjusted HR 0.87, p=0.21 for cohort 2 vs cohort 5). However, risk of repeat 
revascularization was significantly lower in cohorts 4 and 5 compared to cohort 2 (adjusted HR 0.85, p=0.045 and adjusted HR 0.83, p=0.02, 
respectively).
Conclusions: Despite treating a significantly more complex patient population with PCI for coronary atherosclerosis, there appears to be no 
increase in the risk of death or myocardial infarction by five years. In addition, risk of repeat revascularization appears to be lower in later cohorts.
